HealthDay News — For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk treated with metformin, the risk for major adverse cardiovascular events is highest for glipizide as a ...
Highest risk seen with glipizide versus other sulfonylureas and DPP4 inhibitors as second-line therapy. (HealthDay News) — For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results